Generex Oncology

NuGenerex Immuno-Oncology is a clinical-stage biotechnology company and a subsidiary of Generex Biotechnology Corporation, focusing on the development of immunotherapies for cancer and infectious diseases. The company's core technology is the proprietary Ii-Key platform, which enhances the potency of peptide vaccines by modulating the immune system's MHC class II pathway to trigger a robust T-cell response. Its lead candidate, AE37, is a HER2/neu peptide vaccine that has undergone Phase 2 clinical testing for the prevention of breast cancer recurrence. NuGenerex aims to leverage its platform to create targeted vaccines that provide long-term immunity against various malignancies.